Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 10/20 | 0.46 |
| ▸ | LTA4H | P09960 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005176 | 1.00 | CASR (0.46) | CASRLTA4HKDM4EALDH1A1CYP3A4 | |
| SCHEMBL177265 | 0.82 | LTA4H (0.52) | CASRLTA4HMEN1KMT2A | |
| SCHEMBL12327073 | 0.79 | CASR (0.60) | CASRCYP3A4 | |
| SCHEMBL25760375 | 0.79 | CASR (0.60) | CASRCYP3A4 | |
| SCHEMBL11038416 | 0.75 | LTA4H (0.61) | LTA4HKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6005259 | 0.75 | CASR (0.79) | CASRLTA4H | |
| SCHEMBL14471709 | 0.75 | CASR (0.79) | CASRLTA4H | |
| SCHEMBL176843 | 0.75 | LTA4H (0.53) | CASRLTA4HMEN1KMT2ASLC1A3 | |
| SCHEMBL6004434 | 0.75 | LTA4H (0.53) | CASRLTA4HMEN1KMT2ASLC1A3 | |
| SCHEMBL176722 | 0.74 | CASR (0.65) | CASRLTA4HALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2345636-B1 | CASR AGONIST | AJINOMOTO KK (JP) | 2016-03-30 | — | — | EP | claimed |
| EP-2345636-B1 | CASR AGONIST | AJINOMOTO KK (JP) | 2016-03-30 | — | — | EP | disclosed |
| US-9174932-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9000208-B2 | Glutamate derivatives or salts thereof | AJINOMOTO CO., INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-8877739-B2 | Prophylactic agent or therapeutic agent for diabetes or obesity | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20140303122-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8796485-B2 | CaSR agonists | AJINOMOTO CO., INC. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | AJINOMOTO CO., INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2551262-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | Ajinomoto Co., Inc. (JP) | 2013-01-30 | — | — | EP | disclosed |
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | AJINOMOTO CO., INC. (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20110251418-A1 | CASR AGONISTS | AJINOMOTO CO., INC. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2345636-A1 | CASR AGONIST | Ajinomoto Co., Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017603-A1 | GLUTAMATE DERIVATIVES OR SALTS THEREOF | CASR, GIPR, GRPR | CASR 1/4885LTA4H 651/4885KDM4E 4016/4885 |
| US-20140303122-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | CASR 1/4885LTA4H 2221/4885KDM4E 3886/4885 |
| US-20130102570-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY | GPR119, GIPR, CASR | CASR 3/4885LTA4H 1419/4885KDM4E 4756/4885 |
| US-20110251418-A1 | CASR AGONISTS | CASR, GIPR, GRIK5 | CASR 1/4885LTA4H 2221/4885KDM4E 3886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.